18FDG-PET for early prediction of complete response to lapatinib and capecitabine in HER2-positive metastatic breast cancer: a case report.
Ferdinando Riccardi(Ospedale Antonio Cardarelli), Giacomo Cartenì(Ospedale Antonio Cardarelli), Carmela Barbato(Ospedale Antonio Cardarelli), Maria Giuseppa Vitale(University of Modena and Reggio Emilia), Martino Trunfio(Fatebenefratelli Hospital), Carmela Mocerino(Ospedale Antonio Cardarelli), Giovanna Carrillo(Fatebenefratelli Hospital), Salvatore Minelli(Fatebenefratelli Hospital)
Cited by 0
Related Papers
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab
|Clinical Cancer Research|2019|240
First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial
|Journal of Clinical Oncology|2012|234
Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis
|Annals of Oncology|2009|205
Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial
|Journal of Clinical Oncology|2017|186
Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study
|The Journal of Clinical Endocrinology & Metabolism|2019|180